Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2026-01-09 @ 5:02 AM
Study NCT ID:
NCT02041533
Status:
COMPLETED
Last Update Posted:
2023-03-02
First Post:
2014-01-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-03-27
Start Date Type:
ACTUAL
Primary Completion Date:
2016-07-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-27
Completion Date Type:
ACTUAL
First Submit Date:
2014-01-19
First Submit QC Date:
None
Study First Post Date:
2014-01-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-06-26
Results First Submit QC Date:
None
Results First Post Date:
2017-07-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-02
Last Update Post Date:
2023-03-02
Last Update Post Date Type:
ACTUAL